Clofarabine

Generic Name
Clofarabine
Brand Names
Clolar, Evoltra
Drug Type
Small Molecule
Chemical Formula
C10H11ClFN5O3
CAS Number
123318-82-1
Unique Ingredient Identifier
762RDY0Y2H
Background

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...

Indication

For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.

Associated Conditions
Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
Associated Therapies
-
Clinical Trials
Related News

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

First Posted Date
2010-04-12
Last Posted Date
2017-10-19
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT01101880
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

Stanford University, Stanford, California, United States

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Acute Myelogenous Leukemia
Interventions
Drug: clofarabine
First Posted Date
2010-03-19
Last Posted Date
2014-03-19
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
14
Registration Number
NCT01090167
Locations
🇯🇵

Nagoya Daini Red Cross Hospital, Aichi, Japan

🇯🇵

National Hospital Organization Nagoya Medical Center, Aichi, Japan

🇯🇵

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

and more 3 locations

The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia

Phase 1
Withdrawn
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Clofarabine
First Posted Date
2010-02-09
Last Posted Date
2015-04-10
Lead Sponsor
Northwestern University
Registration Number
NCT01065545

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: Clofarabine
First Posted Date
2010-02-05
Last Posted Date
2014-03-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
76
Registration Number
NCT01063257
Locations
🇫🇷

Institut Paoli-Calmettes, Marseille, France

🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

Hôpital Saint-Louis, Paris, France

and more 2 locations

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

First Posted Date
2009-12-31
Last Posted Date
2024-02-01
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
18
Registration Number
NCT01041508
Locations
🇺🇸

Nationwide Childrens Hospital, Columbus, Ohio, United States

🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

🇺🇸

Vanderbilt Children's Hospital, Nashville, Tennessee, United States

and more 3 locations

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

First Posted Date
2009-12-14
Last Posted Date
2019-03-01
Lead Sponsor
Nohla Therapeutics, Inc.
Target Recruit Count
29
Registration Number
NCT01031368
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

First Posted Date
2009-12-03
Last Posted Date
2018-10-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
63
Registration Number
NCT01025154
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Phase 1
Terminated
Conditions
Myelodysplastic Syndrome
Interventions
Drug: Clofarabine
First Posted Date
2009-10-29
Last Posted Date
2016-06-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
4
Registration Number
NCT01003678
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date
2009-10-06
Last Posted Date
2018-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT00990249
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1
Terminated
Conditions
Acute Lymphoblastic Leukemia
First Posted Date
2009-09-24
Last Posted Date
2020-08-12
Lead Sponsor
University of California, San Diego
Target Recruit Count
6
Registration Number
NCT00983528
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

🇺🇸

UCSD Medical Center, San Diego, California, United States

🇺🇸

Rady Children's Hospital, San Diego, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy